Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
This research is collecting information from existing patient records to check the safety of a medicine called nonacog beta pegol, which is used to treat haemophilia B. Instead of directly involving new patients, scientists are looking at data already gathered by large healthcare registries, such as PedNet and the European Haemophilia Safety Surveillance System (EUHASS). These registries contain information about many patients, including any side effects they might have experienced while using this medicine. The goal is to bring together this existing safety information to get a clearer picture of how well the treatment is tolerated in people with haemophilia B. This helps researchers and doctors understand the medicine better and ensure patient safety.
At a glance
What is this study about?
This study is about carefully checking the safety of a medicine called nonacog beta pegol, which is used to treat a bleeding disorder called haemophilia B. Instead of running a new trial where patients take the medicine and are monitored, this study works differently. Researchers are looking at information that's already been collected from large healthcare databases, often called 'registries'. These registries keep records of how people with haemophilia B are treated and any health issues, including side effects, they might have.
The main registries involved are PedNet and the European Haemophilia Safety Surveillance System (EUHASS). These are big systems that collect health data from many patients across different countries. The study will look through these records specifically for information about people who have taken nonacog beta pegol and note down any side effects or 'adverse events' they experienced. They might also include data from other national or international registries if they have information on this medicine.
This kind of study is important because it allows scientists to gather a wide range of real-world safety information from many patients without needing to start new clinical trials. By looking at existing data, they can build a more complete picture of the medicine's safety profile, helping doctors and patients make informed decisions about treatment.
Key takeaways
- This study is collecting safety information about a haemophilia B medicine called nonacog beta pegol.
- It uses existing patient data from large medical registries, not new patient involvement.
- Data collected is about any side effects experienced by patients.
- Your individual privacy is protected as all collected data is anonymised.
- The goal is to better understand the medicine's safety in the real world.
- This research helps improve future treatments for haemophilia B.
Who may be eligible?
This study isn't looking for new patients to take part directly. Instead, it's collecting information that has already been gathered from people with haemophilia B who are part of certain healthcare registries.
So, if you are a person with haemophilia B and your medical information is already included in registries like PedNet or the European Haemophilia Safety Surveillance System (EUHASS), or similar national and international registries, then your anonymised data might be part of this study.
Essentially, there aren't any 'rules' for you to meet to join this study, as it's not asking for your direct involvement. It's simply using existing, anonymised records.
- Are you a person with haemophilia B?
- Have you been treated with the medicine nonacog beta pegol?
- Is your medical information included in a large healthcare registry like PedNet or EUHASS?
- Do you understand that this study doesn't require any direct action from you?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
You don't need to do anything to participate in this study. It's not a typical clinical trial where you would visit a clinic, take medication, or have tests. This study is collecting information that has already been recorded about patients like you from large medical databases (registries). Your personal details will not be used; only information about your treatment and any side effects will be gathered in an anonymised way. Therefore, there are no visits, assessments, or follow-up appointments required from you, and no specific duration for your 'involvement' as you are not actively participating.
Potential risks and benefits
Locations (2)
- PedNet Haemophilia RegistryBaarn, Netherlands
- European Haemophilia Safety Surveillance RegistrySheffield, United Kingdom
Common questions
What is haemophilia B?
Haemophilia B is a rare inherited disorder where your blood doesn't clot properly due to a lack of a specific protein called Factor IX. This can lead to longer bleeding after an injury or surgery, and sometimes spontaneous bleeding.
What is nonacog beta pegol?
Nonacog beta pegol is a medicine used to treat haemophilia B. It works by replacing the missing Factor IX protein, helping the blood to clot normally.
Will my personal information be shared?
No, your personal information will not be shared. This study collects data from registries, but all the information is anonymised, meaning your identity is protected and cannot be linked back to you.
Do I need to do anything for this study?
No, you don't need to do anything. This study simply looks at existing anonymous information from medical records. You won't be asked to visit a clinic or take any new medications.
How does this study help people with haemophilia B?
By gathering information on how nonacog beta pegol affects many patients, researchers can get a better understanding of its safety. This knowledge helps doctors make the best treatment choices and improves care for everyone with haemophilia B.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.